The Hetero Ring Has At Least Seven Members Patents (Class 514/450)
-
Publication number: 20140162988Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140163095Abstract: The invention provides methods of treating breast cancer in subjects having locally advanced or metastatic breast cancer.Type: ApplicationFiled: December 4, 2013Publication date: June 12, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Alton KREMER, Peter Tarassoff, Claudio Savulsky, Martin Olivo, Yi He, D. Matthew Guo
-
Publication number: 20140162987Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140155415Abstract: The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 4, 2012Publication date: June 5, 2014Inventors: Michael David Bartberger, Michael D. Croghan, Christopher H. Fotsch, Mark H. Norman, Lewis Dale Pennington, Andreas Reichelt, David J. St. Jean, JR., Christopher M. Tegley
-
Patent number: 8741889Abstract: The present invention provides a method for treating a patient having cancer comprising administering to the patient a therapeutically effective amount of compound (1), or a pharmaceutically acceptable salt thereof, having the formula: The present invention also provides a kit containing the above compound.Type: GrantFiled: April 19, 2012Date of Patent: June 3, 2014Assignee: Hoffmann-La Roche IncInventors: John Frederick Boylan, Leopoldo Ladores Luistro, Kathryn Elizabeth Packman
-
Patent number: 8741948Abstract: The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.Type: GrantFiled: August 22, 2012Date of Patent: June 3, 2014Assignee: Cosmo Technologies Ltd.Inventors: Mauro Ajani, Roberta Bozzella, Giuseppe Celasco, Roberto Villa
-
Publication number: 20140147492Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.Type: ApplicationFiled: March 28, 2012Publication date: May 29, 2014Applicant: TSINGHUA UNIVERSITYInventors: Yongzhang Luo, Yang Chen, Yan Fu, Lin Jia, Guodong Chang
-
Publication number: 20140142169Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.Type: ApplicationFiled: January 24, 2014Publication date: May 22, 2014Applicant: NESTEC S.A.Inventors: Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
-
Patent number: 8729120Abstract: This invention is directed to a method of treating depression in a subject, comprising the step of administering a therapeutically effective amount of a conventional antidepressant and, in addition, administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member Rx selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected fType: GrantFiled: October 26, 2005Date of Patent: May 20, 2014Assignee: SK Biopharmaceuticals Co., Ltd.Inventor: Jonathan Sporn
-
Patent number: 8722700Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.Type: GrantFiled: May 13, 2013Date of Patent: May 13, 2014Assignee: Wyeth LLCInventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
-
Publication number: 20140128357Abstract: The disclosure relates to methods of using brassinosteroid compounds, including those defined by formula I or a derivative thereof, for inducing an anabolically favorable state for growth, repair, and maintenance of skeletal muscle and skin.Type: ApplicationFiled: December 13, 2011Publication date: May 8, 2014Applicant: Rutgers UniversityInventors: Ilya Raskin, Debora Esposito, Slavko Komarnytsky, Thirumurugan Rathinasabapathy, Leonel Rojo Castillo
-
Publication number: 20140128353Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Biocopea LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140113891Abstract: Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.Type: ApplicationFiled: April 17, 2013Publication date: April 24, 2014Inventors: Alan E. Tomkinson, Xi Chen, Barbara Dziegielewska, Alexander D. Mackerell, Shijun Zhong, Gerald M. Wilson
-
Patent number: 8703812Abstract: The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: GrantFiled: July 30, 2012Date of Patent: April 22, 2014Assignee: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel L. Alkon
-
Publication number: 20140107060Abstract: Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.Type: ApplicationFiled: December 16, 2013Publication date: April 17, 2014Applicant: University of North Carolina at WilmingtonInventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais, Sophie Michelliza
-
Publication number: 20140107084Abstract: The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.Type: ApplicationFiled: October 3, 2013Publication date: April 17, 2014Applicants: ProCom One, Inc., Somaxon Pharmaceuticals, Inc.Inventors: Philip Jochelson, Neil B. Kavey
-
Publication number: 20140100268Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.Type: ApplicationFiled: September 6, 2013Publication date: April 10, 2014Applicant: NEKTAR THERAPEUTICSInventors: Wen Zhang, Xuyuan Gu, Stephanie Allums-Donald, Jennifer Riggs-Sauthier
-
Patent number: 8691808Abstract: The present disclosure provides compounds having affinity for the M2 proton channel, useful for the treatment of viral infections such as influenza, which are of the Formula (I): wherein R1, R2, and Y are as defined herein. Methods of preparing the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds in the treatment of viral infections such as influenza are also provided.Type: GrantFiled: May 18, 2012Date of Patent: April 8, 2014Assignee: Influmedix, Inc.Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
-
Patent number: 8691867Abstract: The present invention is a method for the treatment of alcohol abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and/or formula (II) as herein defined.Type: GrantFiled: December 18, 2006Date of Patent: April 8, 2014Assignee: Janssen Pharmaceutica NVInventors: Virginia L. Smith-Swintosky, Allen B. Reitz
-
Publication number: 20140094462Abstract: Sonic Hedgehog modulators and methods of use thereof are provided for.Type: ApplicationFiled: February 28, 2013Publication date: April 3, 2014Inventors: Sara Buhrlage, Chris Dockendorff, Mike Foley, Han-Je Kim, Andrew Germain, Lawrence MacPherson, Partha Nag, Stuart Schreiber, Amal Ting, Michel Weiwer, Willmen Youngsaye
-
Publication number: 20140093592Abstract: The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: Janssen Pharmaceutica NVInventors: Jaskaran Singh, Lodewijk Ivo Caers
-
Publication number: 20140088079Abstract: The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.Type: ApplicationFiled: June 1, 2012Publication date: March 27, 2014Applicant: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon KIM, Dong Ho Hong, Misuk Kang
-
Publication number: 20140088158Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: SANOFIInventors: Josef PERNERSTORFER, Heinz-Werner KLEEMANN, Matthias SCHAEFER, Alena SAFAROVA, Marcel PATEK
-
Publication number: 20140088182Abstract: The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors.Type: ApplicationFiled: June 12, 2013Publication date: March 27, 2014Applicant: Massachusetts Eye and Ear InfirmaryInventors: Vassiliki Poulaki, Joan W. Miller
-
Patent number: 8680111Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.Type: GrantFiled: March 5, 2013Date of Patent: March 25, 2014Assignee: Pfizer Inc.Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
-
Publication number: 20140080779Abstract: The present invention is directed to the use of macrocyclic lactones, in particular avermectins, in the treatment of conditions whose formation, occurrence, development or growth is associated with aberrant Wnt signalling in particular the treatment of colorectal cancer.Type: ApplicationFiled: May 1, 2012Publication date: March 20, 2014Applicant: UNIVERSITE DE GENEVEInventors: Ariel Ruiz Altaba, Christophe Mas
-
Publication number: 20140080832Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.Type: ApplicationFiled: November 13, 2013Publication date: March 20, 2014Applicant: MANNKIND CORPORATIONInventors: John Bruce PATTERSON, David Gregory LONERGAN, Gary A. FLYNN, Qingping ZENG, Peter V. PALLAI
-
Patent number: 8673890Abstract: The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.Type: GrantFiled: October 28, 2010Date of Patent: March 18, 2014Assignee: Janssen Pharmaceutica NVInventors: Han-Cheng Zhang, Bruce Maryanoff, Kimberly White, Stephen C. Yabut, Hong Ye, Cailin Chen
-
Patent number: 8673949Abstract: Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.Type: GrantFiled: June 1, 2011Date of Patent: March 18, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Charles F. Albright, Donna Marie Barten, Francis Y. Lee
-
Publication number: 20140072663Abstract: A method is provided for treating an individual for a malarial infection, in particular drug-resistant species of Plasmodium, including administering to the individual in need of such treatment a composition comprising an extract containing an effective amount of one or more anti-malarial di- or tri-terpene compounds. Potent and effective extracts containing the anti-malarial compounds can be derived from Luo Han fruit and Stevia leaves, including combinations of the same, for the purpose of treating and preventing malaria in an inexpensive manner from readily available commodities. In one embodiment, the composition is administered orally in a solid or liquid ingestible form.Type: ApplicationFiled: September 10, 2011Publication date: March 13, 2014Applicant: FEBRIS BIO-TECH LIMITEDInventors: Garth Selwyn Smith, Lixin Zhang, Huanqin Dai
-
Publication number: 20140073676Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
-
Publication number: 20140073604Abstract: Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Applicant: UNIVERSITY OF NORTH CAROLINA AT WILMINGTONInventor: UNIVERSITY OF NORTH CAROLINA AT WILMINGTON
-
Patent number: 8669376Abstract: The present invention concerns groups of compounds derived from tunicates of the Synoicum species, as well as to pharmaceutical compositions comprising these compounds, and uses thereof. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in the effective treatment of cancers, particularly malignant melanomas, colon cancer, and renal cancer cell lines.Type: GrantFiled: September 18, 2006Date of Patent: March 11, 2014Assignees: University of South Florida, The UAB Research FoundationInventors: Bill Baker, Thushara Diyabalanage, James B. McClintock, Charles D. Amsler
-
Publication number: 20140066408Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.Type: ApplicationFiled: January 14, 2013Publication date: March 6, 2014Applicant: REATA PHARMACEUTICALS, INC.Inventor: REATA PHARMACEUTICALS, INC.
-
Publication number: 20140057844Abstract: The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies.Type: ApplicationFiled: December 2, 2011Publication date: February 27, 2014Inventors: Tin Tin Su, Gan Zhang
-
Publication number: 20140051750Abstract: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicants: PROCOM ONE, INC., SAMAXON PHARMACEUTICALS, INC.Inventors: Roberta L. Rogowski, Susan Ellen Dubé, Philip Jochelson, Neil Barton Kavey
-
Publication number: 20140051036Abstract: There are described tooth filling materials and dental varnishes for inhibiting the biofilm formation of Streptococcus mutans containing (a) a quantity of an active substance for inhibiting the biofilm formation, (b) a material for forming a structure for the uptake and delayed release of the active substance and (c) a filling material system. Another aspect of this invention relates to a method for producing tooth filling materials or dental varnishes according to the invention for inhibiting the biofilm formation of Streptococcus mutans. The present invention also relates to a kit comprising tooth filling materials or dental varnishes according to the invention and one or more additional constituents. There are also described methods for inhibiting the biofilm formation of Streptococcus mutans, methods for producing a dental component which inhibits the biofilm formation and the use of the active substance for producing a dental material.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicants: Helmholtz-Zentrum fuer Infektionsforschung GmbH, VOCO GmbhInventors: Irene Wagner-Doebler, Andree Barg
-
Publication number: 20140051678Abstract: The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells.Type: ApplicationFiled: November 24, 2011Publication date: February 20, 2014Applicant: STEMERGIE BIOTECHNOLOGY SAInventors: Virginie Clement-Schatlo, Thomas Fessard, Riccardo Cribiu
-
Patent number: 8653285Abstract: An aminopropylidene derivative having excellent histamine receptor antagonistic action, a compound which is useful as a pharmaceutical composition, especially as an active ingredient, having alleviated side effects in the central nervous system is described. In the aminopropylidene derivative, R1 and R2, which may be identical or different, stand for a hydrogen, a substituted carbonyl, a substituted carbonylalkyl, and acrylic acid, excluding a case where both are hydrogen; R3 and R4, which may be identical or different, stand for hydrogen, an alkyl which may be substituted with phenyl, or the like; A stands for unsubstituted or an oxo; B stands for a carbon or an oxygen; one of X and Y stands for a carbon and the other stands for a sulfur, a broken line part stands for a single bond or a double bond, and a wavy line stands for cis-form and/or trans-form.Type: GrantFiled: July 31, 2009Date of Patent: February 18, 2014Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Kunihiko Higashiura, Takashi Ogino, Taizo Ito, Koji Kunimasu, Kazuhito Furukawa
-
Publication number: 20140044777Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.Type: ApplicationFiled: October 23, 2013Publication date: February 13, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Hiroshi KIKUCHI, Kenji HYODO, Hiroshi ISHIHARA
-
Publication number: 20140045841Abstract: The present invention provides a method for inhibiting the growth of cancer stem cells, particularly colorectal cancer stem cells, liver cancer stem cells, lung cancer stem cells or breast cancer stem cells, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of antimycin A or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Inventors: Chi-Ying F. Huang, Chi-Tai Yeh, Chun-Hung Wu, Yu-Wen Liu
-
Publication number: 20140039011Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Applicant: SANOFIInventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
-
Patent number: 8642613Abstract: A process for treating a patient with leukemia or an aplastic anemia having cells with inclusions that stain with anti-E. canis antibodies or antibodies to other Ehrlichia or Anaplasma is disclosed. That process comprises administering to the patient (i) an antibacterial amount of a rifamycin, (ii) an antibacterial amount of a quinolone, or a mixture of (i) and (ii).Type: GrantFiled: September 17, 2009Date of Patent: February 4, 2014Assignee: Sphingomonas Research Partners, L.P.Inventor: Charles A. Kallick
-
Publication number: 20140024705Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: April 6, 2012Publication date: January 23, 2014Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcom Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
-
Publication number: 20140024704Abstract: A process for the preparation of olopatadine hydrochloride starting from an advanced intermediate.Type: ApplicationFiled: July 12, 2013Publication date: January 23, 2014Inventors: Andrea Castellin, Clark Ferrari, Marco Galvagni
-
Publication number: 20140017187Abstract: The invention relates to 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound.Type: ApplicationFiled: July 1, 2013Publication date: January 16, 2014Applicant: Merck Patent GmbHInventors: Soheila ANZALI, Francis Contard, Jean Jacques Zeiller
-
Patent number: 8628794Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.Type: GrantFiled: July 29, 2004Date of Patent: January 14, 2014Assignee: Novartis AGInventor: Ute Isele
-
Publication number: 20140007865Abstract: A methodology for administering topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose in children is disclosed. Moreover, an ophthalmic product is provided for practicing the methodologies.Type: ApplicationFiled: September 10, 2013Publication date: January 9, 2014Inventor: G. Michael Wall
-
Publication number: 20140011867Abstract: The present invention discloses use of borrelidin for preventing and controlling phytophthora root rot of soybean. The present invention also discloses formulations of borrelidin seed coating agents and wettable powders and preparation methods thereof. Borrelidin exhibits significant effects on Phytophthora sojae. As compared with the conventional fungicide metalaxyl which is used for preventing and controlling phytophthora root rot of soybean, the mycelial growth inhibition assay indicates that the IC50 and IC95 values of borrelidin are 1/62 and 1/263, respectively, of those of metalaxyl. In the indoor pot-culture experiment, the seed coating agent and wettable powder exhibit significant controlling effects on phytophthora root rot of soybean.Type: ApplicationFiled: March 25, 2011Publication date: January 9, 2014Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Wensheng Xiang, Jidong Wang, Xiangjing Wang, Chongxi Liu, Dianliang Gong, Hua Bai
-
Patent number: 8623908Abstract: Use of tellurium-containing compounds for treating conditions in which inhibition of caspase-1/interleuFkin-1? enzyme (ICE) is beneficial is disclosed.Type: GrantFiled: March 22, 2010Date of Patent: January 7, 2014Assignee: Biomas Ltd.Inventors: Michael Albeck, Benjamin Sredni